Sareum announced positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases. Sareum believes that dual TYK2/JAK1 inhibition offers the potential for increased efficacy in psoriasis, compared with existing approved oral therapies. The results are summarised as follows: • Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achie ....